PMID: 7515071Mar 1, 1994Paper

Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunodeficiency

Journal of Clinical Immunology
J WaniewskiL Hammarström

Abstract

Replacement therapy, using subcutaneous infusions of gamma-globulin, is being applied increasingly for antibody-deficient patients, as this form of treatment has been found to be related to a very low frequency of adverse systemic reactions. However, the uptake of IgG from subcutaneous tissue may be low, owing to degradation locally, especially for the IgG3 molecule. Therefore, the kinetics of IgG and IgG-subclass concentrations in the sera of 23 patients with common variable immunodeficiency was investigated during 18 months of subcutaneous infusions of gamma-globulin (100 mg/kg/week). Seventeen patients were previously treated with intramuscular injections or intravenous infusions. The mean serum IgG level increased twice in the previously treated patients and four times in the previously untreated patients. A steady state was reached after 6 months if the subcutaneous infusions were given weekly and after 1 week if the patients were given daily infusions for 5 consecutive days and, thereafter, weekly infusions. The fractional catabolic rate of IgG (4.1-5.9% per day) was found to be at the lower limit reported for normal controls, if 100% bioavailability of the infused IgG was assumed. The fractional contents of IgG subclasse...Continue Reading

Citations

Aug 30, 2008·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Meredith L Moore, James M Quinn
Jun 1, 1994·Immunological Reviews·L HammarströmC I Smith
Oct 15, 1998·Archives of Disease in Childhood·J GasparA Jones
Jun 23, 2011·Therapeutic Advances in Neurological Disorders·Min-Suk YoonRalf Gold
Apr 4, 2007·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Ann Gardulf
Sep 4, 2014·Expert Review of Clinical Immunology·Richard L Wasserman
Dec 12, 2012·International Reviews of Immunology·Isaac MelamedZvi Spirer
Oct 1, 2015·Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology·Fonda JiangAndrew G Ayars
Oct 23, 2008·Immunology and Allergy Clinics of North America·Maria Garcia-LloretTalal A Chatila
Oct 23, 2008·Immunology and Allergy Clinics of North America·Francisco A Bonilla
Jul 2, 2016·Therapeutic Advances in Neurological Disorders·Verena I LeussinkMark Stettner
Oct 1, 1995·Human Psychopharmacology·S J Van den Berg
Nov 4, 2009·Clinical and Experimental Immunology·S MisbahH D Ochs
Jul 19, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·C Lindsay DeVane
Nov 2, 2019·Journal of Clinical Immunology·Christine AnterasianBob Geng
Oct 15, 2013·Journal of Neurology, Neurosurgery, and Psychiatry·Yusuf A Rajabally
Nov 30, 2011·Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology·Miriam HoernesJanine Reichenbach
Apr 27, 2017·Einstein·Ekaterini Simões GoudourisWilma Carvalho Neves Forte
Jul 11, 2012·Clinical and Experimental Immunology·J S OrangeB Grimbacher
Jun 3, 2016·Journal of the Peripheral Nervous System : JPNS·Dario CocitoAristide Merola
Apr 7, 2017·Therapeutic Advances in Neurological Disorders·Gisa EllrichmannChristiane Schneider-Gold
Oct 16, 2013·Current Opinion in Allergy and Clinical Immunology·Helen Chapel, Ann Gardulf
Sep 4, 2009·Journal of Neuroimmunology·L HammarströmA Gardulf

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.